Sumitomo Pharma (4506 JP): North America Continue To Be Robust in Q1FY27, Enzomenib Progressing Well
​Sumitomo Pharma's Q1FY27 revenue rose 20% YoY to ¥129.5B, driven by strong sales in North America. Orgovyx and Gemtesa saw significant revenue...
109 Views
Primer: Sumitomo Pharma (4506 JP) - Jul 2026
North American Growth Engine: The company's revenue trajectory is heavily reliant on its North American operations, specifically the robust...
125 Views
Curator's Cut: Soft Commodities' Hard Truths, Pricing China's Hi-Tech & Sumitomo Pharma's Placement
​This Curator's Cut highlights supply-side risks in agri-commodities, China hard-tech IPOs, and Sumitomo Pharma's share placement. Share your topic...
345 Views
Sumitomo Pharma (4506 JP): America Drives FY26, To Be Continued in FY27, Enzomenib in Pivotal Phase
​Sumitomo Pharma sees strong revenue growth in FY26 driven by North America. Momentum to continue in FY27. Profits to see some downside on R&D cost...
132 Views
Sumitomo Pharma (4506 JP): Placement Is In Line With “Boost 2028” Plan, R&D in Focus
Sumitomo Pharma announced the placement price to be ÂĄ1990 per share. Net proceeds of ÂĄ111.6B yen is expected to be used for R&D in oncology (~...
270 Views